Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 2:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Disease Risk Clear all
Completed Not applicable Interventional Results available

Aerosolization During Upper Endoscopy

NCT06006078
View directory record Official record
Conditions
Infectious, Gastro-Intestinal Disorder, Safety Issues
Interventions
Endoscopic Patient Facemask
Device
Lead sponsor
Anthony Lembo
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Sep 28, 2026, 2:22 AM EDT
Withdrawn Phase 2 Interventional

Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Nivolumab or Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Observation Compared With Adjuvant Nivolumab in Treatment-Naive High-risk Melanoma Participants

NCT04495010
View directory record Official record
Conditions
Melanoma
Interventions
Nivolumab, Ipilimumab
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
12 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
23
States / cities
Gilbert, Arizona • Tucson, Arizona • San Francisco, California + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2021 · Synced Sep 28, 2026, 2:22 AM EDT
Completed Phase 2 Interventional

S9712: Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage III Non-small Cell Lung Cancer

NCT00003158
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, etoposide, paclitaxel, radiation therapy
Drug · Radiation
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2007
U.S. locations
86
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 55 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2012 · Synced Sep 28, 2026, 2:22 AM EDT
Active, not recruiting Phase 2 Interventional

A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer

NCT04486378
View directory record Official record
Conditions
Colorectal Cancer Stage II, Colorectal Cancer Stage III
Interventions
RO7198457 intravenous (IV), Observational group (no intervention)
Drug · Other
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older
Enrollment
327 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
15
States / cities
Greenbrae, California • Indianapolis, Indiana • Minneapolis, Minnesota + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 28, 2026, 2:22 AM EDT
Completed Phase 2 Interventional

Clofarabine Plus Cytarabine in Patients With Previously Untreated Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome

NCT00065143
View directory record Official record
Conditions
Leukemia, Myeloid, Myelodysplastic Syndromes
Interventions
clofarabine, Ara-C
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
50 Years to 74 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 6, 2018 · Synced Sep 28, 2026, 2:22 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Preventing Cigarette Use Among Urban Youth Via an M-Health Primary Care Preventive Intervention

NCT03855410
View directory record Official record
Conditions
Tobacco Use, Drug Use, Adolescent Behavior, Alcohol Use, Sexual Risk Behavior
Interventions
S4E, Attention-Matched Control Group
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
13 Years to 21 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
2
States / cities
Ann Arbor, Michigan • Ypsilanti, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 25, 2019 · Synced Sep 28, 2026, 2:22 AM EDT
Recruiting Phase 3 Interventional

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

NCT05946213
View directory record Official record
Conditions
Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
Interventions
Biospecimen Collection, Bone Scan, Computed Tomography, External Beam Radiation Therapy, Magnetic Resonance Imaging, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Body Radiation Therapy
Procedure · Radiation · Other
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older · Male only
Enrollment
1,209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2041
U.S. locations
402
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Little Rock, Arkansas + 303 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Sep 28, 2026, 2:22 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Providing Suboxone and PrEP Using Telemedicine

NCT04521920
View directory record Official record
Conditions
Opioid Use, Opioid-use Disorder, Risk Reduction, Hiv
Interventions
Suboxone, PrEP
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
3
States / cities
Charlotte, North Carolina • Durham, North Carolina • Wilmington, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 8, 2023 · Synced Sep 28, 2026, 2:22 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Social Work Intervention Focused on Transitions

NCT02232126
View directory record Official record
Conditions
Study Focus: 30-day Rehospitalizations Among At-risk Older Adults Randomized to a Social Work-driven Care Transitions Intervention, Heart Disease, Diabetes, Hypertension, Cancer, Depression, Asthma, Chronic Heart Failure, Chronic Obstructive Pulmonary Disease, Stroke
Interventions
SWIFT home intervention
Other
Lead sponsor
University of Southern California
Other
Eligibility
65 Years to 110 Years
Enrollment
181 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
2
States / cities
Los Angeles, California • Pasadena, California
Source: ClinicalTrials.gov public record
Updated Nov 8, 2023 · Synced Sep 28, 2026, 2:22 AM EDT
Completed Not applicable Interventional

Healthy Heart Habits-2

NCT06440278
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
Behavioral Activation for Health and Depression (BA-HD), Enhanced Usual Care
Behavioral · Other
Lead sponsor
The Miriam Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
3
States / cities
Minneapolis, Minnesota • Greenville, North Carolina • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Sep 28, 2026, 2:22 AM EDT
Completed Phase 1 Interventional

Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant

NCT02485535
View directory record Official record
Conditions
Acute Myeloid Leukemia, de Novo Myelodysplastic Syndrome, Myelodysplastic Syndrome, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndrome
Interventions
Laboratory Biomarker Analysis, Selinexor
Other · Drug
Lead sponsor
University of Chicago
Other
Eligibility
Not listed
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 12, 2021 · Synced Sep 28, 2026, 2:22 AM EDT
Completed Phase 1 Interventional

Novel PET/CT Agents and MRS/MRI in Prostate CA and High Risk Prostate Cancer: An Inter-SPORE Collaboration

NCT00987376
View directory record Official record
Conditions
Prostate Cancer
Interventions
Diagnostic Imaging: C11 choline PET; C11 acetate PET; and MRI Spectroscopy
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Male only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 12, 2016 · Synced Sep 28, 2026, 2:22 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Soy Isoflavones and Breast Cancer Risk Reduction

NCT00204490
View directory record Official record
Conditions
Breast Cancer
Interventions
isoflavones, carbohydrate
Dietary Supplement
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
30 Years to 42 Years · Female only
Enrollment
197 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2023
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated May 15, 2024 · Synced Sep 28, 2026, 2:22 AM EDT
Completed Phase 2 Interventional Results available

Evaluation the Treatment of Tamoxifen of Low/Intermediate Risk Bladder Tumors

NCT02197897
View directory record Official record
Conditions
Bladder Cancer
Interventions
Tamoxifen Citrate
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
21 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 12, 2021 · Synced Sep 28, 2026, 2:22 AM EDT
Completed Not applicable Interventional

Endourology Disease Group Excellence (EDGE) Consortium: Antibiotics (Abx) for Percutaneous Nephrolithotomy (PCNL) Part 2

NCT02829060
View directory record Official record
Conditions
Nephrolithiasis, Urinary Tract Infection (UTI), Sepsis
Interventions
Nitrofurantoin 100 MG, 7d, Gentamicin, 5mg/kg, Ampicillin 2g, Nitrofurantoin 100 mg, 48 hrs, Gentamicin, 80 mg, 7d, Gentamicin, 80 mg, 48hr
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
Not listed
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 5, 2025 · Synced Sep 28, 2026, 2:22 AM EDT
Completed Not applicable Interventional

Home Telemedicine to Optimize Health Outcomes in High-Risk Youth With Type 1 Diabetes

NCT03324438
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Home Telehealth T1D C2oYoT1-HR, Personalized Behavioral Health, Personalized Adherence Feedback
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
10 Years to 17 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 20, 2022 · Synced Sep 28, 2026, 2:22 AM EDT
Recruiting Phase 4 Interventional

Dual Antiplatelet Therapy Escalation From Standard-dose Clopidogrel to Low-Dose Prasugrel in Patients With High Bleeding and Ischemic Risk Undergoing PCI: A Prospective, Randomized Pharmacodynamic Study (TAILOR-BLEED-2)

NCT07025148
View directory record Official record
Conditions
Coronary Arterial Disease (CAD), Percutaneous Coronary Intervention (PCI)
Interventions
Prasugrel, Clopidogrel
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Sep 28, 2026, 2:22 AM EDT
Recruiting Phase 1 Interventional

Ropeginterferon for High Risk JAK2 Clonal Hematopoiesis

NCT07249840
View directory record Official record
Conditions
JAK2 Mutation
Interventions
Ropeginterferon
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Sep 28, 2026, 2:22 AM EDT
Recruiting No phase listed Observational

Molecular Profiling for Risk Stratification in Appendiceal Cancer

NCT07587268
View directory record Official record
Conditions
Appendiceal Cancer, Appendiceal Adenocarcinoma
Interventions
DNA Methylation Profiling, m6A Epitranscriptomic Profiling
Diagnostic Test
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Durate, California
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Sep 28, 2026, 2:22 AM EDT
Completed Phase 2 Interventional Results available

Cediranib Maleate in Treating Patients With Relapsed, Refractory, or Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

NCT00475150
View directory record Official record
Conditions
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), de Novo Myelodysplastic Syndromes, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes, Untreated Adult Acute Myeloid Leukemia
Interventions
cediranib maleate, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
5
States / cities
Washington D.C., District of Columbia • Jacksonville, Florida • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2017 · Synced Sep 28, 2026, 2:22 AM EDT
Completed Not applicable Interventional

S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer

NCT01097278
View directory record Official record
Conditions
brca1 Mutation Carrier, brca2 Mutation Carrier, Breast Cancer
Interventions
cholecalciferol, placebo
Dietary Supplement · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 50 Years · Female only
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
360
States / cities
Anniston, Alabama • Mobile, Alabama • Anchorage, Alaska + 230 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2017 · Synced Sep 28, 2026, 2:22 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Stroke COunseling for Risk REduction

NCT03076125
View directory record Official record
Conditions
Stroke
Interventions
SCORRE, Attention-Control Activity
Behavioral
Lead sponsor
Georgia State University
Other
Eligibility
20 Years to 35 Years
Enrollment
116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 12, 2018 · Synced Sep 28, 2026, 2:22 AM EDT
Recruiting Phase 2 Interventional

Effect of Acetylcholinesterase Inhibitors on Bone Metabolism

NCT06041789
View directory record Official record
Conditions
Osteoporosis
Interventions
Donepezil, Memantine
Drug
Lead sponsor
Duke University
Other
Eligibility
50 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 20, 2026 · Synced Sep 28, 2026, 2:22 AM EDT
Recruiting Not applicable Interventional

Prophylactic TCRaB+ and CD19+ Depleted Donor Lymphocyte Infusion After Allogeneic Stem Cell Transplant in High-Risk Patients With Hematologic Malignancies

NCT07285668
View directory record Official record
Conditions
Hematologic Malignancies
Interventions
Allogeneic donor TCRαβ+/CD19+ cell-depleted peripheral blood mononuclear cells
Device
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 80 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 13, 2026 · Synced Sep 28, 2026, 2:22 AM EDT